Document Detail

Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
MedLine Citation:
PMID:  19340526     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To investigate whether integrated fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) can differentiate benign from adrenal malignant lesions on the basis of maximum standardized uptake value (SUV(max)), tumor/liver (T/L) SUV(max) ratio, and CT attenuation value (Hounsfield Units; HU) of unenhanced CT obtained from FDG-PET/CT data. METHODS: We studied 30 patients with 35 adrenal lesions (16 adrenal benign lesions, size 16 +/- 5 mm, in 15 patients; and 19 adrenal malignant lesions, 24 +/- 12 mm, in 15 patients) who had confirmed primary malignancies (lung cancer in 23 patients, lymphoma in 2, esophageal cancer in 2, hypopharyngeal cancer in 1, prostate cancer in 1, and 1 patient in whom lesions were detected at cancer screening). All patients underwent PET/CT at 1 h post FDG injection. Diagnosis of adrenal malignant lesions was based on interval growth or reduction after chemotherapy. An adrenal mass that remained unchanged for over 1 year was the standard used to diagnose adrenal benign lesions. Values of FDG uptake and CT attenuation were measured by placing volumetric regions of interest over PET/CT images. Adrenal uptake of SUV(max) >/= 2.5 was considered to indicate a malignant lesion; SUV(max) < 2.5 was considered to indicate a benign lesion. In further analysis, 1.8 was employed as the threshold for the T/L SUV(max) ratio. Unenhanced CT obtained from PET/CT data was considered positive for adrenal malignant lesions based on a CT attenuation value >/= 10 HU; lesions with a value < 10 HU were considered adrenal benign lesions. Mann-Whitney's U test was used for statistical analyses. RESULTS: SUV(max) in adrenal malignant lesions (7.4 +/- 3.5) was higher than that in adrenal benign lesions (2.1 +/- 0.5, p < 0.05). The CT attenuation value of adrenal malignant lesions (27.6 +/- 11.9 HU) was higher than that of adrenal benign lesions (10.1 +/- 12.3 HU, p < 0.05). In differentiating between adrenal benign and malignant lesions, a CT threshold of 10 HU corresponded to a sensitivity of 57%, specificity of 94%, accuracy of 74%, positive predictive value of 92% and negative predictive value of 65%. An SUV(max) cut-off value of 2.5 corresponded to a sensitivity of 89%, specificity of 94%, accuracy of 91%, positive predictive value of 94% and negative predictive value of 88%. The T/L SUV(max) ratio was 1.0 +/- 0.2 for adrenal benign lesions and 4.5 +/- 3.0 for adrenal malignant lesions. And T/L SUV(max) ratio cut-off value of 1.8 corresponded to a sensitivity of 85%, specificity of 100%, accuracy of 91%, positive predictive value of 100% and negative predictive value of 83%. CONCLUSIONS: FDG-PET/CT with additional SUV(max) analysis improves the diagnostic accuracy of adrenal lesions in cancer patients.
Masahiro Okada; Taro Shimono; Yoshihiro Komeya; Rina Ando; Yuki Kagawa; Takashi Katsube; Masatomo Kuwabara; Yukinobu Yagyu; Seishi Kumano; Izumi Imaoka; Norio Tsuchiya; Ryuichiro Ashikaga; Makoto Hosono; Takamichi Murakami
Related Documents :
3863436 - Fine needle aspiration of myelolipoma of the adrenal gland. report of a case with compu...
18559306 - Bilateral primary adrenal non-hodgkin's lymphoma - a case report and review of the lite...
12894286 - Malignant paraganglioma with vertebral metastasis: case report.
14999546 - Idiopathic unilateral adrenal hematoma: report of a case.
7124356 - Colposcopic pattern of cervicitis, dysplasia and pre-invasive cancer of the uterine cer...
3738726 - Steroid-induced regression of primary malignant lymphoma of the brain.
Publication Detail:
Type:  Journal Article     Date:  2009-04-02
Journal Detail:
Title:  Annals of nuclear medicine     Volume:  23     ISSN:  0914-7187     ISO Abbreviation:  Ann Nucl Med     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-12     Completed Date:  2009-08-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8913398     Medline TA:  Ann Nucl Med     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  349-54     Citation Subset:  IM    
Department of Radiology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenal Gland Neoplasms / pathology,  radiography*,  radionuclide imaging*
Adrenal Glands / pathology*,  radiography,  radionuclide imaging
Aged, 80 and over
Fluorodeoxyglucose F18 / diagnostic use*,  metabolism
Liver / metabolism
Middle Aged
Positron-Emission Tomography
Retrospective Studies
Tomography, X-Ray Computed
Reg. No./Substance:
63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tc-99m sestamibi parathyroid imaging in a rare case of parathyroid lipoadenoma.
Next Document:  Relationship between maximum standardized uptake value (SUVmax) of lung cancer and lymph node metast...